Pharmaceutical company AstraZeneca plans to sell its molecule antibiotics business to Pfizer in a deal that will be valued in excess of $1.5 billion when rights, royalties and other payments are included.
The sale marks a thawing of relations between the British company and New York-based Pfizer after an acrimonious battle to avoid a takeover just a few years ago.
Continue Reading Below
Under the deal, AstraZeneca will sell the commercialization and development rights in most markets globally outside the United States. It includes an upfront payment of $550 million.
Luke Miels, the head of the antibiotics business unit at AstraZeneca, says the company is "pleased that our strong science in antibiotics will continue to serve a critical public health need through Pfizer's dedicated focus on infectious diseases."